ARYL-TRIFLATES AND RELATED COMPOUNDS

Abstract: Aryltriflates and related compounds having general formula (1) wherein Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; wherein R1 is CF3, (C1-C8)alkyl, -CH2-(C3-C8)cycloalkylalkyl, substituted phenyl, substituted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thiophenylethyl or substituted 2-thiophenylpropyl; possess both good pharmacodynamic and good pharmacokinetic properties and are thus useful drugs.

Description: ARYL-TRIFLATES AND RELATED COMPOUNDS. Field of the Invention The present invention is directed toward new aryltriflates, and their pharmaceuti¬ cally acceptable salts, to processes for preparing such compounds, pharmaceutical preparations of such compounds and the use of such compounds in manufacture of a pharmaceutical preparation. Pharmaceutical preparations of these compounds are useful for peripheral and central nervous system disorders in mammals. Background of the Invention Aryl triflates are used as intermediates in organic syntheses. They can thus be removed via reduction (NEt 3 +HCOO-) or substituted by other groups like CN and COOR (Oda, R., Kagaku (Kyoto) 1987, 42, 710-11 ; Cacchi, S. et al., Tetrahedron Lett 1986, 27, 5541-4; Chambers, M. R. I. et al., J. Chem. Soc, Perkin Trans 1989, 1, 1365-6; Kotsuki, H. et al., Synthesis 1990; Martorell, G. et al., Tetrahedron Lett 1990, 31, 2357-60; Peterson, G. A. et al., Tetrahedron eft 1987, 28, 1381-4; Roth, G. P. et al., J. Org. Chem. 1991, 56, 3493-6; Saa, J. M. et al., J. Org. Chem. 1990, 55, 991-5; Subramanian, L R. et al., Synthesis 1984; Chambers, M. R. I. et al., J. Chem. Soc, Perkin Trans 1989, 1, 1365-6.; Takagi, K. et al., Bull. Chem. Soc. Jpn. 1991 , 64, 1118-21 ; EP-A1 399982; Liu, Y. et a!., Bioorg. Med. Chem. Lett. 1991 , 1, 257-62. One aryltriflate with biological activity (5-HTTA affinity in a CNS preparation) is known ( EP-A1 399982; Liu, 1991 supra). In addition, the triflate of the analgetic substance paracetamol has been used as an intermediate in the conversion of the phenol into its cyano analogue (Chambers, 1989, supra; Takagi, 1991 , supra). Enzymatic deactivation of drugs (the Cytochrome P450 isoenzyme system) is a well known phenomenon, in particular phenols and methoxylated aryls are in general easily oxidized in the liver and elsewhere where these enzyme systems are active (e. g. the gastric mucosa and the lungs). Inactivation of phenols can take place via direct conjugation (sulphation and glucoronidation) and/or via initial oxidation and then conjugation. Obviously, the inhibition of such enzymatic deactivation of drugs is highly desired, and the object of the present invention is to provide therapeutically effective drugs having a low liability for enzymatic deactivation. in particular drugs with better pharmacokinetic properties than the corresponding hydroxy and/or alkoxy substi¬ tuted analogues. It has now been found that triflate derivatives of drugs comprising a hydroxyaryl group or a similar group possess both good pharmacodynamic and good pharmaco¬ kinetic properties including a high resitance against enzymatic deactivation. Summary of the invention This invention relates to aryltriflates and related compounds having the general Formula 1 : Formula 1 or pharmaceutically acceptable acid addition salts thereof, wherein Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; and Ri is CF 3 , (C Cs) alkyl, -CH 2 -(C 3 -Cβ) cycloalkylalkyl, substituted phenyl, substi¬ tuted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thio¬ phenylethyl or substituted 2-thiophenylpropyl; except the compounds wherein Ar is 2-(dipropylamino)-tetralin-8-yl or 4- acetamidophenyl. In a preferred embodiment, the invention is directed to compounds of Formula 1 ; wherein Ri is CF 3 . Processes for preparation of these compounds, their pharmaceutical use and pharmaceutical preparations comprising such compounds constitute further aspects of the invention. Detailed Description of the Invention As used herein the term (C n -C m ) is inclusive such that a compound of (C Cβ) would include compounds of one to 8 carbons and their isomeric forms. Alkyl refers to an branched or unbranched aliphatic hydrocarbon radical such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neo-pen- tyl, n-hexyl, isohexyl, n-heptyl, isoheptyl, and n-octyl. Halogen means fluoro, chloro, bromo or iodo. It will be apparent to those skilled in the art that some compounds of this invention may contain chiral centers. The scope of this invention includes all enantiomeric or diastereomeric forms of Formula 1 compounds either in pure form or as mixtures of enantiomers or diastereomers. The therapeutic properties of the compounds may to a greater or lesser degree depend on the stereochemistry of a particular compound. Pure enantiomers as well as enantiomeric or diastereomeric mixtures are within the scope of the invention. "Compounds which has a therapeutic, biological activity when they, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group" may be any therapeutical effective compounds comprising an aryl group carrying such a substituent. Preferably, the compound is a drug acting in the central nervous system, in particular a dopamine agonist or antagonist, a dopamine autoreceptor agonist, a 5- HTIA ligand, 5-HTID ligand, a 5-HT 2 antagonist, an antipsychotic, a sigma ligand, or a melatonine analogue, beta blocker, analgesic, etc. Specific examples of Ar appears from the following table showing examples of compounds of the invention. In the table, R_ is as defined above; R2 designates C Cs alkyl, CH 2 -(C3-C8) cycloalkylalkyl, arylalkyl, phenylethyl or 2-thiophenylethyl; R3 designates C Cs alkyl, CH2-(C3-Cs) cycloalkylalkyl, arylalkyl, phenylethyl or 2-thiophenylethyl; X is CH 2 , O or S; and Y is CH 2 , O or S. AntigsthrngtiPS Terbutalin analogues Salbutamol analogue Dopamine agonists Roxindole analogues Dopamine agonists cont'd Dopamine autoreceptor antagonists D1 agonists and/or antagonists SK&F38393 analogues SCH23390 analogue -HT1 A agonists R 2 and R 3 are not at the same time propyl trans 5-HT1A lioands 5-HT1D liαands Sumatriptan analogue Sigma ligands analogue Anti-Alzheimers 7-Methoxytacrine analogue Neuroleptics Clozapine analogue Chlorpromazine and levomepromazine analogue Melatonine analogues Analgesics morphine analogue analogue acetyl salicylic acid analogue Ketobemidone analogue Beta-blockers prenalterol analogue oxprenolol analogue The pharmaceutically acceptable acid addition salts of the compounds may be for¬ med by reaction with non-toxic organic or inorganic acids in an aqueous miscible solvent, such as acetone or ethanol, and subsequent isolation of the salt by concen¬ tration and cooling or by reaction with an excess of the acid in aqueous immiscible 5 solvent, such as ethyl ether or chloroform, with the desired salt separating directly. Exemplary of such organic salts are those with maleic, fumaric, benzoic, ascorbic, embonic, succinic, oxalic, bis methylene-salicylic, methanesulfonic, ethane- disulfonic, acetic, propionic, tartaric, salicylic, citric, gluconic, lactic, malic, mandelic, o cinnamic, citraconic, aspartic, stearic, palmitic, itaconic, glycolic, p-amino-benzoic, glutamic, benzene sulfonic and theophylline acetic acids as well as the 8- halotheophyllines, for example 8-bromo-theophylline. Exemplary of such inorganic salts are those with hydrochloric, hydrobromic, sulfuric, sulfamic, phosphoric and nitric acids. Of course, these salts may also be prepared by the classical method of 5 double decomposition of appropriate salts, which is well known to the art. In clinical practice the compounds of the present invention will normally be adminis¬ tered orally, rectally or by injection, in the form of pharmaceutical preparations comprising the active ingredient either as a free base or as a pharmaceutically 0 acceptable non-toxic, acid addition salt, such as the hydrochloride, lactate, acetate, sulfamate salt, in association with a pharmaceutically acceptable carrier. The use and administration to a patient to be treated in the clinic would be readily apparent to a person of ordinary skill in the art. 5 In therapeutical treatment the suitable daily doses of the compounds of the invention are from about 1 mg to 2000 mg for oral application, preferentially 50-500 mg, and 0.1 to about 100 mg for parenteral application, preferentially 0.5-50 mg daily doses. The daily dose will preferably be administered in individual dosages one to 4 times daily and the dosage amounts are based on an individual having a o weight of 70 kg. The compounds of this invention have high oral potency and long duration of action, as compared to their hydroxy or alkoxy analogues. Both these pharmacokinetic features are beneficial to effective clinical treatment. The compounds of this invention may be obtained by the general general synthetic strategy exemplified in Scheme 1 : Scheme 1 The triflating agent is conveniently triflic anhydride (Method A), N-phenyltrifluoro- methanesulfonimide (Method B) or triflic acid chloride (Method C). Starting materials for the preparation of the compounds of the invention are commercially available, or they can be obtained by the methods described below or by methods known in the art. Specific examples of starting materials for their preparation are shown below. In the formulas X and Y are as defined above: Dopamine agonists: Starting materials CAS RN's: trans racemic: 110311-52-9 trans-4aS,10bS: 93601-83-3 trans-4aR,10bR : 93601 -82-2 cis racemic: 82171-94-6 cis-4aS,10bR: 93601 -81-1 cis-4aR,10bS: 93601-80-0 CAS RN's: trans racemic: 110311-53-0 trans-4aS,10bS: 110311-50-7 trans-4aR,10bR : 103302-90-5 cis-racemic: 110311 -55-2 cis-4aS,10bR: 93601 -81 -1 cis-4aR,10bS: 93601 -80-0 11-hydroxy aporphine (-)-apomorphine: CAS RN: 58-00-4 Dopamine autoreceptor antagonists: Starting materials CAS RN: cis-4aR,10bS: 93601-80-0 D1 agonists and/or antagonists: Starting materials -HT1A agonists: Starting materials CAS RN's: trans-racemic: 82172-01-8 trans-4aS,10bS: 131484-03-2 r trans-4aR,10bR: 131484-02-1 cis-racemic: 82172-00-7 cis-4aR,10bS: 109062-23-9 cis-4aS,10bR: 109062-21-7 CAS RN's: racemic: 127165-21-3 -HT1A agonists: Starting materials cont'd CAS RN's: racemic: 127165-07-5 R enantiomer: 129568-16-7 S enentiomer: 127253-43-4 CAS RN's: trans-racemic: 110826-30-7 1S-trans: 110901-82-1 1 R-trans: 110901-81-0 CAS RN's: trans-racemic: 110826-37-4 1S-trans: 110901-84-3 1 R-trans: 110901-83-2 CAS RN's: 6aS-enantiomer: 135529-45-2 6aR-enantiomer: 111635-19-9 de name 129301-34-4 5-HT1A ligands: Starting materials CAS RN: racemic: 127033-10-7 R-enantiomer: 127126-18-5 S-enantiomer: 127126-21-0 5-HT1 D ligands: Starting materials in Sigma ligands; starting materials CAS RN's: trans racemic: 110311-53-0 trans-4aS,10bS: 110311-50-7 trans-4aR,10bR : 103302-90-5 cis-racemic: 110311-55-2 cis-4aS,10bR: 93601-81-1 cis-4aR,10bS: 93601-80-0 - Anti-Alzheimers: Starting materials Neuroleptics: Starting materials clozapine analogue m. Melatonine analogues: Starting materials alkaline hydrolysis material Analgesics: Starting materials morphine Analgesics: Starting materials cont'd Salicylic acid Ketobemidone Beta-blockers: Starting materials Antiathmatics: Starting materials terbutalin salbutamol In the following the invention is further illustated by way of examples which must not be construed as limiting of the invention. Example 1 8-Trifluoromethyl(sulfonyl)oxy-2-(acetamido)tetralin (Method A). 8-OH-2-(acetamido)tetralin (ref: Swier Copinga et al. oral presentation at the Xllth Int. Symposium on Med. Chem. in Basel, September 13-17, 1992) (0.22 g: 1.1 mmol) was dissolved in pyridine (10 mL) and at - 20 °C was added triflic anhydride [RN 358-23-6; from Aldrich] (2.0 mL; 23 mmol) and the reaction mixture was stirred at this temperature for 0.5 h. The temperature was raised to room temperature within 1.5 h and was stirred over night at this temperature. Water was added and the product was extracted with CH 2 CI 2 (10 mL). The organic layer was washed with solutions of NH CI, NaHC0 3 and NaCI and then separated and dried (MgS0 4 ), filtered and the solvent was evaporated under reduced pressure. The remaining oil was chromatographed (Si02) eluting with CH 2 C- 2 -MeOH (10:1). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding a brown solid as the product, which was recrystallized yielding white crystals (100 mg; 28%). MS with chemical ionization (NH 3 ) detection shows M + 1 at m/e=338 and M + 18 at m/e=355. Example 2 8-Trifluoromethyl(sulfonyl)oxy-2-(acetamido)tetralin (Method B). 8-OH-2-(acetamido)tetralin (see above) (0.49 g: 2.4 mmol) was dissolved in CH 2 CI 2 (25 mL) and Et 3 N (0.31 g: 3.1 mmol) was added. Then the mild, triflating agent N-phenyltrif luoromethanesulfonim.de [RN 37595-74-7; from Aldrich] (0.96 g; 2.69 mmol) was added in one portion at room temperature. The reaction mixture was monitored with GC and after one night all starting material was consumed. The solvent and the Et3N were evaporated and the remaining oil was dissolved in CH 2 CI 2 and washed 3 times with water and the organic layer was separated and washed once with NaCI saturated water, separated and dried (Na 2 Sθ 4 ). The solvent was evaporated and the remaining oil (240 mg) was purified by flash chro atography (Si0 2 60 mesh) eluting with CH 2 CI 2 :MeOH (10:1). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding 40 mg (6%) of the pure triflated product as a colourless oil. The mass spectrum (chemical ionization with NH 3 ) showed: M+1 at m/e=338 and M+18 at m/e=355. 1H-NMR (200 MHz, CDCI 3 , TMS) shows: δ 7.0-7.3 (3H, ArH); 5.6-5.8 (1 H, NH); 4.2-4.4 (1 H, C2); 1.5-3.3 (6H, C1 , C3, C4); 2.0 (3H, COCH3). The electronegativity of the OTf group is indicated by the downfield shift of the aromatic protons from 6.3-6.9 in the starting material (8-OH-2-(acetamido)tetralin) to 7.0-7.3 in the triflated product (with respect to the electronic effects of the triflate group, see also ref: Stang, P. and Anderson, A. G., J. Org. Chem. 1976, 41 , 781 ). Example 3. 5-Trifluoromethyl(sulfonyl)oxy-(N-acetyl)-tryptamine (Method B). N-Acetyl-5-hydroxy tryptamine [RN 1210-83-9] was triflated according to Method B and was isolated as an oil after chromatography and evaporation of the solvents in 60% yield. MS shows (chemical ionization with NH 3 ) m/e = 351 (M+1). 1H-NMR (200 MHz, CDCI 3 , TMS) shows: δ 1.95 (s, 3H), 2.95 (t,2H), 3.55 (t, 2H), 6.0 (t, 1 H, NHCO), 7.00-7.10 (m, 2H, aromatic) 7.30-7.50 (m, 2H, aromatic), 9.30 (s, 1 H, NH-indole) 1 3 C-NMR (CDCI3, 50 MHz); 23.2 (CH 3 ), 25.0 (CH 2 ), 39.9 (CH 2 ), 111.0 (CH, aromatic), 112.4 (CH, aromatic), 113.4 (C, aromatic), 114.9 (CH, aromatic), 124.7 (CH, aromatic), 127.6 (C, aromatic), 135.2 (C, aromatic), 143.2 (CH, aromatic), 170.6 (CO); the CF 3 signals apperar at ca 110, 116, 122 and 128. Example 4. 8-Trifluoromethyl(sulfonyl)oxy-2-(N-methyl-N-propargyl-amino)tetralin (Method B). The hydrochloride of 8-hydroxy-2-(N-methyl-N-propargyl-amino)tetralin (Presented in Durk Dijkstra's Thesis 1992 from the Department of Med. Chem., Univ. Centre of Pharmacy, Antonius Deusinglaan 2, NL-9713 AW Groningen, The Netherlands) (50 mg, 0.20 mmol) was suspended in CH 2 CI 2 (5 mL) and Et 3 N (0.1 mL) was added. The mixture was stirred until all crystals were dissolved. Then the mild, triflating agent N-phenyltrifluoromethanesulfonimide [RN 37595-74-7; from Aldrich] (75 mg; 0.21 mmol) was added in one portion at room temperature. The reaction mixture was monitored with GC and TLC, and after 20 h all starting material was consumed. The solvent and the Et 3 N were evaporated and the remaining oil was dissolved in ether (10 mL) and washed 3 times with NaCI saturated water, separated and dried ( gSθ 4 ). The solvent was evaporated and the remaining oil was dissolved in EtOH (5 mL) and fumaric acid (0.23 g, 0.20 mmol) dissolved in EtOH (1 mL) was added and the solvent was evaporated. The remaining solid was recrystaliized from i-propylacetate. The mass spectrum (chemical ionization with NH 3 ) showed: M+1 at m/e=348. A second synthesis was performed as described above with a change in workup. The raw oil after extraction and evaporation was purified by chromatography (S1O 2 ), eluting with EtOAc:hexane (1 :3). The base was converted to its HCI salt with HCI-sturated ether. Example 5. 3-TrifluoromethyI(sulfonyl)oxy-Morphine (Method B). Morphine hydrochloride 1.1 g (3.3 mmol) was stirred in CH 2 CI 2 (50 mL) and EtβN (0.49 mL, 0.36 g: 3.6 mmol) was added. Then the mild, triflating agent N-phenyltri- fluoromethanesulfonimide [RN 37595-74-7; from Aldrich] (1.3 g; 3.6 mmol) was added in one portion at room temperature. The reaction mixture was monitored with GC and after 2 h all starting material was consumed. The solvent and the Et 3 N were evaporated and the remaining oil was dissolved in CH 2 CI 2 (50 mL) and washed 3 times with 5% Na 2 C0 3 and the organic layer was separated and washed once with NaCI saturated water, separated and dried (Na 2 S0 4 ). The solvent was evaporated and the remaining oil (1.9 g) was purified by chromatography (Siθ 2 60 mesh) eluting with CH 2 CI 2 :MeOH (1:1). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding 0.86 g (63%) of the pure triflated product as an oil. This oil (0.74 g, 1.8 mmol) was dissolved in warm EtOH (25 mL) and added to a warm solution of fumaric acid (0.22 g, 1.9 mmol). Evaporation and recrystallization from refluxing EtOAc gave a gel, which was filtered and dried, yielding 600 mg of white crystals melting at 111-116 °C. The mass spectrum (chemical ionization with NH3) showed: M+1 at m/e=418. 1H-NMR (200 MHz, CDCI3, TMS) shows: δ 1.84 - 1.96 (m, 1 H), 2.10 (dt, 7 = 4.8 Hz, 1 H), 2.22 - 2.43 (M, 5H), 2.58 -2.76 (M, 2H), 2.86 (br 5, 1 H) 3.08 (d. 7 = 19.2 Hz, 1 H) 3.38 (dd. 7 = 6.1 , 3.4 Hz, 1 H), 4.17 - 4.24 (M, 1 H), 5.01 (dd, 7 = 6.4, 1.2, 1 H), 5.24 - 5.32 (M, 1 H), 5.65 - 5.73 (M. 1 H), 6.63 (d. 7 = 8.3 Hz, 1 H) 6.88 (d. 7 = 8.5 Hz, 1 H) 13C-NMR (CDCI3, 50 MHz); 20.91 (CH 2 ), 35.20 (CH 2 ), 40.42 (CH), 42.95 (CH), 43.33 (C), 46.02 (CH 2 ), 58.43 (CH), 66.48 (CH), 93.57 (CH), 115.42 (C), 120.24 (CH), 121.02 (CH), 121.80 (C), 128.26 (CH), 130.55 (C), 133.58 (CH), 133.76 (C), 135.70 (C). Example 6. 11-Hydroxy-10-trifluoromethyl(sulfonyl)oxy-aporphine. 3-Trifluoromethansulfonyloxy-morphine (fumarate salt) (100 mg; 0.19 mmol) was stirred for 3 hrs at 105 °C in MeSOsH (5 mL) under N 2 -atmosphere. The reaction mixture was allowed to cool to room temperature and was then diluted with H2O (10 mL). The aquous layer was basified with NaHC03 (s) and then extracted with CH2CI2 (3x25 mL). The organic layers were combined, dried over Na 2 Sθ 4 , filtered and evaporated in vacuo. to give a greenish-white solid (72 mg; 96%). The fumarate salt was formed by mixing the product (36 mg; 0.09 mmol) in EtOH with fumaric acid (10.5 mg) in EtOH and then evaporation of the solvent. MS (chemical ionization with NH3) showed M + 1 at m/e=400. Example 7. 10-Hydroxy-11-trifluoromethyl(sulfonyl)oxy-aporphine. This compound was synthesized from apomorphine x HCl with Method B and gave a product with M+1 at m/e=400 (chemical ionization with NH3) according to GC/MS. Example 8. Trifluoromethanesulfonyl-Dextrorphan (Method A). Dextrorphan tartaric acid salt (1 :1) (1.0 g; 2.46 mmol) was suspended in CH 2 CI 2 5 (100 mL) and Et 3 N (2 mL; 14 mmol) was added and the solution was stirred until all the starting material had dissolved. Then the mild, triflating agent N-phenyltrifluoro- methanesulfonimide [RN 37595-74-7; from Aldrich] (1.05 g; 2.94 mmol) was added in one portion. The reaction mixture was monitored with GC and after 4 h all dextrorphan was consumed. The solvent and the Et 3 N were evaporated and the 10 remaining oil was dissolved in CH 2 CI 2 and washed 3 times with water and the organic layer was separated and washed once with NaCI saturated water, separa¬ ted and dried (Na 2 S0 4 ). The solvent was evaporated and the remaining yellow oil was purified by flash chromatography (Siθ 2 60 mesh) eluting with CH 2 Cl 2 -MeOH (1 :1). The fractions containing pure product were pooled and the solvent was 15 evaporated under reduced pressure, yielding 630 mg (66%) of the pure triflated product as a light yellow oil. This oil was dissolved in EtOH (10 mL) and fumaric acid (190 mg; 1.65 mmol) was dissolved in EtOH (10 mL) and added. The EtOH was evaporated off and the remaining solid was recrystaliized from warm EtOH with cooling to room temperature and scraping with a glass rod. The first crop of crystals 20 were filtered and dried and they weighed 360 mg and melted at 85-90 °C. The mass spectrum (chemical ionization with NH 3 ) showed: M+ + 1 at m/e=390. Example 9. (±)-5-Trifluoromethyl(sulfonyl)oxy-2-(N-propyl-N-2-thienylethylamino)tetralin 25 (5-TfO-N-0437) CMethod B). General procedure: P. J. Stang , Synthesis, 1982, 115-118. To 5-hydroxy-2-(N-pro- pyl-N-2-thienylethylamino)tetraiin (N-0437) (Horn, A. S.; Tepper, P.; Van der Weide, J.; Watanabe, M.; Grigoriades r D.; Seeman, P., Pharm. Weekbi. Sci. 7, 208-211, 1985) (200 mg; 0.57 mmol) in dry pyridine (10 mL) was added triflic anhydride [RN 30 358-23-6; from Aldrich] (1.0 mL; 11 mmol) at -20 °C. The temperature was raised to 0 °C and was maintained there for 48 h, when the solvent was evaporated under reduced pressure. To the residue was added CH 2 CI 2 (50 mL) and the solution was extracted twice with brine (check how this is done). The organic layer was sepa- rated, dried (Na 2 S0 ), filtered and the solvent was evaporated under reduced pressure and the remaining oil was purified by column chromatography (Siθ 2 60 mesh) eluting with petroleum ether : EtOAc (1 :1 ). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding the pure product an oil. The base was converted to its hydrochloride salt with HCI saturated ether. The IR spectrum shows strong absorption bands at: 3000, 1460, 1420, 1210 and 1140 cm -1. MS with EC detection shows: m/e=133 (CF 3 S0 2 ) and m/e=149 (CF 3 SO 3 ) but no M+ could be seen. MS with chemical ionization (NH 3 ) detection shows M + 1 at m/e=448 (M + H+). Example 10. (-)-5-Trifluoromethyl(sulfonyl)oxy-2-(N-propyl-N-2-thienylethylamino)tetralin (S-(-)-5-TfO-N-0437; 5-TfO-N-0923) (Method B). Starting material: S-(-)-5-Hydroxy-2-(N-propyl-N-2-thienylethylamino)tetralin (S-(-)-N-0437; N-0923) (Horn, A. S.; Tepper, P.; Van der Weide, J.; Watanabe, M.; Grigoriades, D.; Seeman, P., Pharm. Weekbl. Sci. 7, 208-211 , 1985; Ten Hoeve, W.; Wijnberg, H., J. Org. Chem. 50, 4508, 1985). Example 11. (+)-5-Trifluoromethyl(sulfonyl)oxy-2-(N-propyl-N-2-thienylethylamino)tetralin (R-(+)-5-TfO-N-0437; 5-TfO-N-0924) (Method B). Starting material: R-(+)-5-Hydroxy-2-(N-propyl-N-2-thienylethylamino)tetralin (R-(+)-N-0437; N-0924) (Horn, A. S.; Tepper, P.; Van der Weide, J.; Watanabe, M.; Grigoriades, D.; Seeman, P., Pharm. Weekbl. Sci. 7, 208-211 , 1985; Ten Hoeve, W.; Wijnberg, H., J. Org. Chem. 50, 4508, 1985). Example 12. 8-(3-trifluoromethyl(sulfonyl)oxy)phenyl)indolizidine (Method B). 8-(3-Hydroxyphenyl)indolizidine (Bøgesø et al. J. Med. Chem. 30, 142-150, 1987) (74 mg; 0.25 mmol) was dissolved in CH 2 CI2 (6 mL) and Et 3 N (68 μL; 0.50 mmol) was added. Then the mild, triflating agent N-phenyltrifluoromethanesulfonimide [RN 37595-74-7; from Aldrich] (89 mg; 0.25 mmol) was added in one portion at room temperature. The reaction mixture was monitored with GC and after one night all starting material was consumed. The solvent and the Et 3 N were evaporated and the remaining oil was dissolved in CH 2 CI 2 and washed 3 times with water and once with 5% Na 2 Cθ 3 (25 mL) and the organic layer was separated and washed once with NaCI saturated water, separated and dried (Na 2 S0 4 ). The solvent was evaporated and the remaining oil (117 mg) was purified by flash chromatography (Siθ 2 60 mesh) eluting with CH 2 C. 2 :MeOH (1 :1). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding 73 mg (84%) of the pure triflated product as an oil. The mass spectrum (chemical ionization with NH 3 ) showed: M+1 at m/e=350. 1H NMR (CDCI 3 , 200 MHz, TMS) shows: δ 1.26 - 2.31 (m, 11 H), 2.44 - 2.62 (m, 1H), 3.15 - 3.24 (m, 2H), 7.10 - 7.41 (m, 4H). 13C NMR (CDCIs, 50 MHz); 20.15 (CH 2 ), 25.41 (CH 2 ), 28.94 (CH 2 ), 32.59 (CH 2 ), 48.61 (CH), 52.49 (CH 2 ), 54.30 (CH 2 ), 69.05 (CH), 119.14 (CH), 120.10 (CH), 121.89 (C), 127.60 (CH), 130.04 (CH), 146.97 (C), 149.62 (C). Example 13. 1-(3-Trifluoromethyl(sulfonyl)oxy)phenyl)-3,4,6,7,8,9-hexa- hydro-9aH-quinolizine (Method B). 1-(3-HydroxyphenyI)-3,4,6,7.8,9-hexahydro-9aH-quinolizine (Bøgesø et al. J. Med. Chem. 30, 142-150, 1987) (130 mg; 0.57 mmol) was dissolved in CH 2 CI 2 (20 mL) and Et 3 N (158 μL; 1.14 mmol) was added. Then the mild, triflating agent N-phenyltrifluoromethanesulfonimide [RN 37595-74-7; from Aldrich] (300 mg; 0.85 mmol) was added in one portion at room temperature. The reaction mixture was monitored with GC and after 5 h all starting material was consumed. The CH 2 CI 2 phase was washed with saturated Na 2 Cθ 3 (50 mL), the water layer was washed with CH 2 CI 2 (30 mL) and the combined organic phases were dried (Na 2 S0 4 ). The solvent was evaporated and the remaining oil was purified by chromatography (S1O 2 60 mesh) eluting with CH 2 Cl 2 :MeOH (1 :1). The fractions containing pure product were pooled and the solvent was evaporated under reduced pressure, yielding 197 mg (82%) of the pure triflated product as a yellow oil. The mass spectrum (chemical ionization with NH 3 ) showed: M+1 at m/e=362. 1H NMR (CDCI 3 , 200 MHz, TMS) shows: δ 1.1 (dp, J=11.7 and 3.0,1 H), 1.2 - 1.5 5 (m, 1 H), 1.5 - 1.8 (m, 4H), 2.1-2.3 (m, 1 H), 2.3-2.6 (m, 3H), 2.8-3.1 (m, 3H), 5.9 (dd, J=5.4 and 2.0, 1 H), 7.1 - 7.4 (m, 4H). 13C NMR (CDCI 3, 50 MHz); 25.10 (CH 2 ), 26.15 (CH 2 ), 29.82 (CH 2 ), 51.06 (CH 2 ), 56.46 (CH 2 ), 62.71 (CH), 119.07 (CH), 119.73 (CH), 126.55 (CH), 126.89 (CH), 10 130.04 (CH), 129.73 (CH), 139.60 (C), 144.10 (C) (note: one quaternary C and CF 3 are not listed due to a too weak signals). Examples 14 1-Methyl-4-propionyl-4-[3-[(trifluoromethyl)sulfonyloxy]phenyl]piperidine, 15 fumarate (ketobemidone triflate) (Method C) (compound C1) To a solution of 1-methyl-4-propionyl-4-(3-hydroxyphenyl)piperidine (ketobemidone, CAS RN : 83544-10-9) (2 g) and triethylamine (1.2 ml) in dichloromethane (25 ml) was added dropwise during 10 minutes trifluoromethansulfonylchloride (1.0 ml) at 0- 5 °C. The mixture was stirred for additionally 1 hour at room temperature. Brine 0 (200 ml) was added and extracted with dichloromethane (3x 50 ml). The combined organic extracts were dried (anh. MgS0 4 ) and dichloromethane evaporated leaving the crude title compound as a visceous oil. The triflate derivative crystallized as the acidic fumarate salt from ethanol. Yield 2.0 g, mp : 164.6-165.4 °C. " iH-NMR (250 MHz, DMSO-de) : δ 0.75 (t, 3H); 2.15 (broad t,2H); 2.30 (q, 2H); 2.40 (s, 3H); 2.5- 5 2.7 (m, 4H); 2.85 (broad s, 2H); 6.55 (s, 2H); 6.95 (s, 1 H); 7.0 (m, 2H); 7.10 (t, 1 H). In a corresponding way the following triflate derivatives were prepared: (±)-7-Chloro-3-methyl-1-phenyl-8-[(trifluoromethyl)sulfonyloxy]-2,3,4,5- 0 tetrahydro-rH-3-benzazepine, oxalate (compound C2). Mp: 167-169 °C (from acetone). 1H-NMR (250 MHz, DMSO-d 6 ) : δ 2.75 (s, 3H); 2.95 (t, 1 H); 3.10 (dd, 1 H); 2.85-3.10 (m, 3H); 4.5-5.2 (m, 4H); 6.45 (s, 1 H); 7.25 (d, 2H); 7.35-7.50 (m, 3H); 7.75 (s, 1H). Prepared from the selective dopamine D_ antagonist SCH 23390 (racemate used) (CAS RN : 138584-32-4). (-J-N.N-diethyl-N-fe-Ktrifluormethy sulfonyloxyJindan-l-yllmethylamine, oxalate (Compound C3). Mp: 120-122 °C (from acetone). 1H-NMR (250 MHz, DMSO-de) : δ 1.15 (t, 6H); 1.9-2.0 (m, 1 H); 2.3-2.4 (m, 1H); 2.8-3.2 (m, 7H); 3.3-3.4 (m, 1H); 3.5-3.6 (m, 1H); 7.30 (dd, 1 H); 7.40 (d, 1 H); 7.55 (d, 1H). Prepared from the corresponding dopamine D 2 agonist (US patent no 4,946,863). (±)-N,N-dipropyl-N-[5-[(trifluormethyl)sulfonyloxy]-2,3-dihydrobenzofuran-3- yl]methylamine, oxalate (Compound C4). Mp: 125-126 °C (from acetone). 1H- NMR (250 MHz, DMSO-d 6 ) : δ 0.90 (t, 6H); 1.55 (dq, 4H); 2.80 (t, 4H); 3.05 (t, 1H); 3.15 (dd, 1 H); 3.9-4.0 (m, 1H); 4.45 (dd, 1 H); 4.75 (t, 1 H); 6.95 (d, 1H); 7.25 (dd, 1 H); 7.55 (d, 1H). Prepared from the corresponding dopamine D 2 agonist (US patent no 4,847,254). (±)-N-methyl-N-propyl-N-[5-[(trifluormethyl)sulfonyloxy]-2,3-dihydrobenzofu- ran-3-yl]methylamine, oxalate (Compound C5). Mp: 138-141 °C (from acetone). 1H-NMR (250 MHz, DMSO-d 6 ) : δ 0.90 (t, 3H); 1.65 (dq, 2H); 2.70 (s, 3H); 2.95 (dt, 2H); 3.20 (t, 1 H); 3.30 (dd, 1 H); 4.0-4.1 (m, 1 H); 4.55 (dd, 1 H); 4.80 (t, 1 H); 6.95 (d, 1H); 7.30 (dd, 1H); 7.55 (d, 1H). Prepared from the corresponding dopamine D 2 agonist (US patent no. 4,847,254). Preparation of mixtures of (±)-3-methyI-1-phenyI-7,8-di[(trifluorome- thyl)sulf ony loxy]-2,3,4,5-tetrahydro- 7 -benzazepine, (±)-8-hydroxy-3-methyl« 1-phenyl-7-[(trifluoromethyl)sulfonyloxy]-2,3,4,5-tetrahydro-rH-3-benzazepine, (±)-7-hydroxy-3-methyl-1-phenyl-8-[(trifluoromethyl)sulfonyloxy]-2,3,4,5- tetrahydro-7H-3-benzazepine, oxalates (mixtures C6 and C7). The free catechole base (1.6 g) liberated from (±)-7,8-dihydroxy-3-methyl-1-phenyI- 2,3,4,5-tetrahydro-7tf-3-benzazepine, HBr (2.0 g) (SK&F 75670, see Arnt and Perregaard : Eur. J. Pharmacol. 1987, 143 , 45-53) was dissolved in dichlomethane (100 ml) containing triethylamine (0.7 g). The mixture was cooled to °C and a solution of trifluoromethansulfonylchloride (1.1 g) in dichloromethane (5 ml) was added dropwise during 10 minutes. After stirring for another hour at room tempera¬ ture water (100 ml) was added. Extraction with dichloromethane (3x 25 ml) and subsequent work-up of the combined organic phases afforded a mixture of com- pounds, which were subjected to column chromatography on silica gel (eluted with diisopropyl ether/tetrahydrofuran/triethylamine 70:20:10). Two fractions were eluted. To the first fraction collected was added oxalic acid in an attempt to crystallize the oxalate salt, however without success. The mass spectrum (chemical ionization with NH 3 ) of this mixture (mixture C6) showed: M+1 at m/e 534 (ditriflate) and M+1 at m/e 402 (mono triflate isomer(s)). Similarly attempts to crystallize oxalic acid salts from the second fraction were unsuccessful. The mass spectrum (chemical ionization with NH 3 ) of the second mixture (mixture C7) also showed: M+1 at m/e 534 (ditriflate) and M+1 at m/e 402 (mono triflate isomer(s)), however in another molucular ratio. Example 15. Compound Roxindole-OTf 6,7-di-OTf-DPAT 2-OTf-N-Pr-Ph-pip 3-OTf-N-Pr-Ph-pip 3-OTf-N-PhEth-Ph-pip 5-CI-8-OTf-N-Pr-N-thienylethyl-2-A trans-9-OTf-PHNO cis-9-OTf-PHNO Triflated nor-Remoxipride Ditriflated isoprenaline Ditriflated terbutalin Tritriflated fenoterol Triflated R-(+)-8-OH-DPAT B M + 1 at m/e=380 [ ] D 25 = +18.2 at c=0.35 in MeOH (base); +52.0 at c=1.00 in MeOH (base) Triflated S-(-)-8-OH-DPAT B M + 1 at m/e=380 [α] D 25 = -24.5 at c=0.44 in MeOH (base); -55.9 at c=1.00 in MeOH (base) Triflated Apocodeine B M + 1 at m/e=414 Triflated 8-OH-2-[N-n-Pr,N-(2-thienyl)ethylamino)tetralin B M + 1 at m/e=448 Triflated 8-OH-2-[N-n-Pr,N-phenylethylamino)tetralin B M + 1 at m/e=442 Triflated S-(-)-N-0437 B M + 1 at m/e=448 [ α ]25= -40.7 at c=62.5 mg/5 mL in MeOH PHARMACHOLOGY The following reliable and well recognised test methods are used to establish the effects of the compounds of the invention: Receptor binding studies. DA Di receptors. Inhibition of 3H-SCH 23390 binding to DA Di receptors in rat striatal membranes was determined as described by Hyttel, J. and Arnt, J. J. Neural. Transm. 1987, 68, 171. DA D 2 receptors. Inhibition of 3H-spiperone binding to DA D 2 receptors in rat striatal membranes as described by Hyttel, J. Ada. Pharmacol. Toxicol. 1986, 59, 387; or Inhibition of 3H-spiperone binding to DA D 2 receptors in calf striatal membranes as described by Krotowska A. et al. Acta. Pharm Suec. 24, 145. Inhibition of 3H-N-0437 binding in calf striatal membranes as described by Van der Weide J et al, Eur. J. Pharmacol. 1986, 134, 211. 5-HT 2 receptors. Inhibition of 3H-ketanserin binding to 5-HT 2 receptors in membranes from rat cortex was determined as described by Hyttel, J. Ada. Pharmacol. Toxicol. 1987, 61, 126. 5-HT 1A receptors. Inhibition of 3H-8-OH-DPAT Binding to Serotonin 5-HT 1A Receptors in Rat Brain in vitro as described by Gozlan H. et al. Nature 1983, 305, 140, and Pazos A et al, Eur. J. Pharmacol. 1985, 106, 539. Sigma Receptors Inhibition by drugs of the binding of 3H-DTG (1 ,3,di-o-tolyl guanidine) to sigma receptors in homogenates or membranes from rat brain without cerebellum as modified from Weberef al. Proc. Natl. Acad. Sci. 1986, 83, 8784. In Vivo Tests Antagonism of SK&F 38393-induced circling behavior in rats with unilateral 6- OHDA lesions. This test is a test for the DA Di receptor antagonistic effect in vivo. The experiments are performed as described by Arnt, J.et al., J. Neural. Transm. 1986, 67, 225-240. Antagonism of Pergolide-induced circling behavior in rats with unilateral 6- OHDA lesions. This test model is used to determine dopamine (DA) D 2 antagonistic effect. (Arnt.J. and J.Hyttel, Eur. J. Pharmacol. 102, 349-354, 1984; Arnt, J. and J. Hyttel, J. Neural. Transm. 67, 225-240, 1986). Quipazine inhibition The test is a test for 5-HT 2 -antagonistic effect testing the ability to inhibit quipazine induced head twitches. The method and test results for some reference substances are published by Arnt et al. (Drug Development Research, 16, 59-70, 1989). Dopamine agonist studies Dopamine agonist effects are studied as described in US patent no. 4,946,863. 8-OH-DPAT Cue Antagonism in Rats. This test model is used to determine the antagonist effects of a test compound on 5- HT-iA receptors in vivo. A related method is described by Tricklebank, M. D., etal, Eur. J. Pharmacol., 1987, 133, 47-56; Arnt, J. Pharmacology & Toxicology, 1989, 54, 165. 8-OH-DPAT Cue Agonism in Rats This test model is used to determine the agonist effects of a test compound on 5- HTIA receptors in vivo. A related method is described by Tricklebank, M. D et al, Eur. J. Pharmacol., 1987, 133, 47-56; Arnt, J. Pharmacology & Toxicology, 1989, 64, 165. The following results have been obtained: The compound (±)-5-Trifluoromethyl(sulfonyl)oxy-2-(N-propyl-N-2-thienylethylami- no)tetralin (5-TfO-N-0437) showed an IC 50 value of 69 nM in the [3H]-spiperone binding assay according to the method of Krotowska A. et al(supra). Furthermore the compounds of Example 14 showed binding affinities in the above 3H-SCH 23390 binding assay as follows: Compound no IC 50 value in nM C2 50 C6 28 C7 85

Claims: WHAT IS CLAIMED: 1. An aryltriflate or a related compound having the general Formula 1 : Formula 1 or pharmaceutically acceptable acid addition salts thereof, wherein Ar is an aromatic or heteroaromatic system of a compound which has a therapeutic, biological activity when it, in the same position, carries a hydroxy, alkyloxy, halo, ester or cyano group; and Ri is CF 3 , (CrCs) alkyl, -CH2-(C 3 -Cβ) cycloalkylalkyl, substituted phenyl, substi¬ tuted benzyl, substituted phenylethyl, substituted phenylpropyl, substituted 2-thio¬ phenylethyl or substituted 2-thiophenylpropyl; except the compounds wherein Ar is 2-(dipropylamino)-tetralin-8-yl or 4- acetamidophenyl. 2. A compound of claim 1 , Formula 1 , wherein Ri is CF 3 . 3. Compounds of claim 1 which are given in Enclosure 1 (at the end of this docu- ment). 4. A method for treating human disorders comprising the administration to a mammal of a therapeutic amount of a compound of Claim 1 or a pharmaceutically acceptable acid addition salt thereof to a patient in need thereof. 5. The method of claim 4, wherein said compound is administered in an amount of from about 1 to about 2000 mg oral daily dose, or from 0.1 to about 100 mg parenteral daily dose.

Inventors: WIKSTROEM HAAKAN, WIKSTROEM, HAAKAN
Applicants: LUNDBECK & CO AS H, H. LUNDBECK A/S
Application year: 1992
Main classification: A61K31
IPC codes: A61K31, A61P25, A61P43, C07C309, C07D209, C07D211, C07D213, C07D221, C07D223, C07D243, C07D279, C07D307, C07D311, C07D333, C07D335, C07D401, C07D455, C07D471, C07D489